Events on 26 September 2023
CONGRESS 2023 - The Blood Film to the Rescue
26/09/2023
Despite major advances in investigating haematological abnormalities, the blood film can still be crucial in diagnosis and patient management. The first major role is the validation of an abnormal blood count and, when it is found to be invalid, finding an explanation for factitious results. Factitiously low platelet counts and factitiously high MCVs are well recognized examples.
When the count is found to be valid, an explanation might be revealed. A blood film may indicate a likely diagnosis within minutes; this can be of vital importance as in acute promyelocytic leukaemia, thrombotic thrombocytopenic purpura, Burkitt lymphoma and certain infections. Sometimes the blood film suggests an uncommon or rare condition the diagnosis of which is important but would otherwise be delayed or elusive.
When the count is found to be valid, an explanation might be revealed. A blood film may indicate a likely diagnosis within minutes; this can be of vital importance as in acute promyelocytic leukaemia, thrombotic thrombocytopenic purpura, Burkitt lymphoma and certain infections. Sometimes the blood film suggests an uncommon or rare condition the diagnosis of which is important but would otherwise be delayed or elusive.
CONGRESS 2023 - Implementing a new laboratory IT system and how to avoid the pitfalls
26/09/2023
Implementing a new laboratory IT system and how to avoid the pitfalls
CONGRESS 2023 - The new Certificate of Expert Practice in Laboratory IT and Clinical Informatics
26/09/2023
The new Certificate of Expert Practice in Laboratory IT and Clinical Informatics
CONGRESS 2023 - Equality, diversity and inclusion: optional extra or innate necessity? (why bother)
26/09/2023
Equality, diversity and inclusion: optional extra or innate necessity? (why bother)
CONGRESS 2023 - Applying sustainability principles in pathology– a reality or a pipe dream?
26/09/2023
Sustainability is the balance between the environment, equity, and economy. It is well documented that our changing climate has severe implications for public and planetary health. As healthcare professionals, we have a responsibility to consider the way we practice and try to reduce any negative impacts of our practice.
This workshop looks at the carbon footprint of the lab and discusses what processes and practices can be adapted to reduce the carbon footprint of pathology practice. It explores the barriers to change and areas to target for improvement.
This workshop looks at the carbon footprint of the lab and discusses what processes and practices can be adapted to reduce the carbon footprint of pathology practice. It explores the barriers to change and areas to target for improvement.
CONGRESS 2023 - Quality issues and accreditation for andrology services
26/09/2023
Quality issues and accreditation for andrology services
CONGRESS 2023 - How to publish your research - A workshop from the British Journal of Biomedical Science team
26/09/2023
This workshop on "How to publish your research" is delivered by the British Journal of Biomedical Science team. The aim of the workshop is to provide attendees with a clear understanding of the publishing process, so they feel empowered to submit their research to a peer-reviewed journal. As the British Journal of Biomedical Science is the official journal of the IBMS the workshop will provide members with the opportunity to discuss how they can engage with their journal.
CONGRESS 2023 - Transplant Assessment and Relative Opportunity Tool (TAROT) for Renal Transplantation: Improving the chance of transplant for immunologically complex patients
26/09/2023
Transplant Assessment and Relative Opportunity Tool (TAROT) for Renal Transplantation: Improving the chance of transplant for immunologically complex patients
CONGRESS 2023 - Narcolepsy and its association with HLA type
26/09/2023
This presentation will introduce basic sleep physiology related to the pathophysiological mechanisms Narcolepsy is a rare but debilitating neurological sleep disorder, with a worldwide prevalence of 25-50 per 100,000 people. Onset is most common during the adolescent years, though a diagnostic delay of around 10 years is common. There is currently no cure, though symptoms can be managed using pharmacotherapy. Biochemistry services provide an important role in confirming a diagnosis of narcolepsy in line with current international guidelines such as the International Classification of Sleep Disorders 3rd edition (ICSD-3).
The aims of this talk are to:
1. Introduce basic sleep physiology related to the pathophysiological mechanisms underpinning narcolepsy.
2. To describe the signs and symptoms of narcolepsy and their impact on patients.
3. To review the diagnosis of narcolepsy including the role of biomarkers such as HLA type and CSF hypocretin.
4. To summarise treatment options for narcolepsy.
The aims of this talk are to:
1. Introduce basic sleep physiology related to the pathophysiological mechanisms underpinning narcolepsy.
2. To describe the signs and symptoms of narcolepsy and their impact on patients.
3. To review the diagnosis of narcolepsy including the role of biomarkers such as HLA type and CSF hypocretin.
4. To summarise treatment options for narcolepsy.
CONGRESS 2023 - Controlled Human Infection Models: Anti-viral immunity in the respiratory tract
26/09/2023
Controlled human infection models (CHIMs) allow researchers to deliberately infect volunteers with a carefully pre-defined viral inoculum and perform detailed investigations. These can examine both pre-existing immune responses and allow longitudinal sampling of multiple immunological compartments following infection. The unique nature of these CHIMs avoid the multiple confounding factors, which tend to limit conventional observational studies of naturally acquired viral infections in patients.
We have successfully established challenge models of influenza (H1N1 and H3N2), Respiratory Syncytial Virus (RSV) and SARS-CoV2, and used a variety of tools (such as multi-parameter flow cytometry, ELISpot, multiplex cytokine and chemokine arrays and transcriptomics) to characterise populations of low-frequency virus-specific CD4+ and CD8+ T cells in both peripheral blood and cells in the upper and lower airways from challenge participants. We have also been able to extend our infection models into vulnerable populations, such as older adults, and use these techniques to investigate fundamental questions about the kinetics, specificities, and functionality of the cell-mediated response in these clinically relevant populations.
Challenge models allow us to probe the immune response to respiratory viral infections in a uniquely detailed manner. These advantages also make challenge models an attractive approach to testing the efficacy of novel vaccines and vaccine platforms, potentially leading to new vaccines and therapeutics, able to generate robust anti-viral immunity, while avoiding the significant risks and costs associated with traditional Phase II/III vaccine trials.
We have successfully established challenge models of influenza (H1N1 and H3N2), Respiratory Syncytial Virus (RSV) and SARS-CoV2, and used a variety of tools (such as multi-parameter flow cytometry, ELISpot, multiplex cytokine and chemokine arrays and transcriptomics) to characterise populations of low-frequency virus-specific CD4+ and CD8+ T cells in both peripheral blood and cells in the upper and lower airways from challenge participants. We have also been able to extend our infection models into vulnerable populations, such as older adults, and use these techniques to investigate fundamental questions about the kinetics, specificities, and functionality of the cell-mediated response in these clinically relevant populations.
Challenge models allow us to probe the immune response to respiratory viral infections in a uniquely detailed manner. These advantages also make challenge models an attractive approach to testing the efficacy of novel vaccines and vaccine platforms, potentially leading to new vaccines and therapeutics, able to generate robust anti-viral immunity, while avoiding the significant risks and costs associated with traditional Phase II/III vaccine trials.